Nucleix Ltd. news
SAN DIEGO & REHOVOT, ISRAEL--(BUSINESS WIRE)--Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced data from two abstracts featuring its Bladder EpiCheck® test at the 36th Annual European Association of Urology (EAU) Virtual Congress.
The first abstract titled, “Real world evidence of alternating cystoscopy/cytolo
SAN DIEGO & REHOVOT, Israel--(BUSINESS WIRE)--Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced the publication of an analysis highlighting that Bladder EpiCheck® can reduce both patient burden and healthcare system costs in the U.S. and European countries for low grade intermediate risk non-muscle invasive
Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, has secured $55 million from a syndicate of leading life science investors in an oversubscribed financing round.
The round was led by RA
-Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, recently announced the launch of its BE Safe @Home project to bring surveillance for recurrence of non-muscle invasive bladder cancer (NMI
SAN DIEGO & REHOVOT, Israel--(BUSINESS WIRE)--Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, recently an